FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burder	n
hours per response.	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

issuer that is inte	of equity securities of nded to satisfy the se conditions of Rule astruction 10.	the			
1. Name and Addres	ess of Reporting Pers	son *	2. Issuer Name and Ticker or Trading Symbol BioSig Technologies, Inc. [BSGM]	S. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner	
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 12/28/2023	Officer (give title Other (specify below)	
C/O BIOSIG TECHNOLOGIES, INC. 55 GREENS FARMS ROAD	If Amendment, Date of Original Filed (Month/Day/Year)	Individual or Joint/Group Filing (Check Applicable Line X Form filed by One Reporting Person Form filed by Many than One Reporting Person			
(Street) WESTPORT	CT	06880		Form filed by More than One Reporting Persor	'
(City)	(State)	(Zip)	—		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

(2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transac Code (In 8)	tion	4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			Securities	Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	(Instr. 3 and 4)		(111501.4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (In 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Stock Option (Right to Buy)	\$0.4742	12/28/2023		A		600,000		(1)	12/27/2033	Common Stock	600,000	\$0	600,000	D	
Restricted Stock Units	(2)	12/28/2023		A		900,000		(3)	(3)	Common Stock	900,000	\$0	900,000	D	

Explanation of Responses:

- 1. One hundred thousand (100,000) of the shares of common stock underlying the stock option shall vest on each monthly anniversary of the date of grant for six consecutive months, provided that the Reporting Person is still providing services to the issuer or a subsidiary on such vesting dates.
- $2. \ Each \ restricted \ stock \ unit \ ("RSU") \ represents \ the \ right \ to \ receive, \ at \ settlement, \ one \ (1) \ share \ of \ common \ stock.$
- 3. This RSU award was granted on December 28, 2023. Upon the issuer's market valuation of \$50,000,000, three hundred thousand (300,000) RSUs shall vest and upon the issuer's market valuation of \$100,000,000, six hundred thousand (600,000) RSUs shall vest, subject to the terms and conditions of the BioSig Technologies, Inc. 2023 Long-Term Incentive Plan and the issuer's standard form of Restricted Stock Unit Award Agreement, provided that the Reporting Person is still providing services to the issuer or a subsidiary on such vesting dates. Notwithstanding the foregoing, upon the occurrence of (i) a change in control, or (ii) a termination of service due to death or total and permanent disability, all unvested RSUs shall immediately become vested RSUs.

/s/ Kenneth Londoner, attorney-infact 01/04/2024

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.